Wilms’ tumor 1 (WT1) has been one of the most widely explored vaccine targets in AML, since it is a leukemia-associated protein overexpressed in leukemic cells with a pivotal role in blast proliferation and differentiation (33). This evidence concerns the gene WT1 and acute myeloid leukemia.